A recent study suggests that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who end conventional lifestyle regimens.
Research printed in a major medical journal demonstrates that while obese people frequently drop about a fifth of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these drugs should be informed of the danger of rapid weight regain when the therapy ends," stated researcher Dr. Susan Jebb.
This pace of recovery means a reversion to original weight in about a year and a half.
Weighing Therapies
The study, which examined 37 of studies involving over 9,000 of patients, compared the results of the injectable medications with older methods.
Researchers point out that individuals who lose weight through dieting usually have a slower weight regain—around 0.1 kg a month—once they finish.
Explaining the Fast Regain
Experts believe the mode of action of the drugs explains the amplified regain.
The injections copy a body's own chemical called GLP-1, which controls appetite.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement leads to hunger is unsuppressed, making excessive eating far more likely."
An Ongoing Condition?
Medical guidelines suggest the injections for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Professionals contend that, due to the high risk of weight regain, the treatment is often life-long.
This perspective is supported by pharmaceutical companies, who note that the findings "highlight the chronic character of excess weight," akin to managing conditions like diabetes.
User Experiences
People who have come off the medication describe a sudden return of appetite.
"It felt as if something that goes on and you're instantly extremely hungry," said one woman.
The struggle is exacerbated if patients have not adopted permanent dietary or behavioural changes during therapy.
Significant Use
Recent estimates indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is more common among women than men.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent solution and lasting health benefits relies on combined behavioural management.
